Itamar Medical is a medical device company focused on the integration of sleep apnea management into the cardiac patient care pathway. The companys core strategies include the development, manufacture, and sale of the FDA-cleared WatchPAT diagnostic product line.
The WatchPAT line is based on the biological PAT signal acquired by the PAT technology, which is proven as a simple, comprehensive, reliable, and scalable alternative to airflow as well as enabling point-of-deployment versatility; and Total Sleep Solutions, a product that includes a field support organization, partnerships, and core and supporting technologies that enable all physicians, and cardiologists in particular, to provide a seamless and full continuum of care to sleep apnea patients as part of their care pathway.
In addition, the company has developed and is currently marketing the EndoPAT system, an endothelial function assessment tool for risk classification used by clinicians, researchers, and pharmaceutical companies to easily and reliably quantify and track arterial health.
In recent years, Itamar Medical has signed a number of strategic marketing agreements for its products, including agreements with Medtronic, Philips, Resmed, and SoClean in the U.S. and Philips Respironics in Japan.